knowledge -WSS

knowledge

author：focus 2025-10-02 23:30:23 - browse：4625

Sorrento Therapeutics — ARIANA DREHSLER/AFP via Getty Images

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group.

A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.-based drug manufacturers rather than companies named in the legislation, even though doing so will be more costly. An executive at a U.S.-based contract development and manufacturing organization, or CDMO, who spoke on condition of anonymity, said that “month to month, new business has gone through the roof.”

Meanwhile, some Chinese suppliers not named in the bill are paradoxically drawing increased interest from biotechs — while hearing from some customers worried those manufacturers could be blacklisted in the future.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： The boys, now 6, who are gene therapy’s ‘edge case’ problem

WSS

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Ukraine taking heavy casualties 10 weeks into its counteroffensive

Decaf coffee targeted by food safety group under obscure FDA rule

Decaf coffee targeted by food safety group under obscure FDA rule

Washington mulls new rules to avert another Change Healthcare

Trump's false claims about Georgia's 2020 election long debunked

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

23andMe had bad news about my health. I wish a person had delivered it

Will generative AI in health care meet the fate of IBM's Dr. Watson?

The high cost of giving birth even with insurance

Washington mulls new rules to avert another Change Healthcare

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

Duchenne breakthrough therapy leaves behind pioneering families

Decaf coffee targeted by food safety group under obscure FDA rule

The cancer drug shortage isn’t new — and neither are the solutions

Evacuations in place as 3 wildfires burn in eastern Washington state

hotspot

Study says nonprofit hospitals fall short in charity care spending

FDA's naming rule on biosimilars has undermined competition

Oprah kicked off a national conversation on obesity. Let's have it

A neonatal nurse in a British hospital has been found guilty of killing 7 babies

Majority of Americans think Trump's Ga. election interference case is serious: POLL

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

hotspot

leisure time

leisure time

knowledge